Market Cap | 2.51M | P/E | 0.01 | EPS this Y | 96.20% | Ern Qtrly Grth | - |
Income | -6.44M | Forward P/E | -0.34 | EPS next Y | 13.90% | 50D Avg Chg | -62.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -86.00% |
Dividend | N/A | Price/Book | 0.30 | EPS next 5Y | - | 52W High Chg | -99.00% |
Recommedations | 2.50 | Quick Ratio | 0.56 | Shares Outstanding | 2.03M | 52W Low Chg | 8.00% |
Insider Own | 5.66% | ROA | -27.07% | Shares Float | 2.34M | Beta | - |
Inst Own | 1.46% | ROE | -15.28% | Shares Shorted/Prior | 46.60K/55.04K | Price | 0.52 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,801,430 | Target Price | 36.00 |
Oper. Margin | - | Earnings Date | Aug 14 | Volume | 216,676 | Change | 0.19% |
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Roth MKM | Buy | Mar 15, 24 |
Roth MKM | Buy | Jan 3, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Romano Sarah | Chief Financial Offi.. Chief Financial Officer | Jan 12 | Sell | 4.20 | 98 | 412 | 20,306 | 01/17/24 |
SAPIRSTEIN JAMES | Chairman, President.. Chairman, President and CEO | Jan 12 | Sell | 4.20 | 166 | 697 | 39,166 | 01/17/24 |
CASAMENTO CHARLES J | Director Director | Sep 15 | Sell | 0.43 | 10 | 4 | 6,098 | 09/18/23 |
CASAMENTO CHARLES J | Director Director | Aug 31 | Sell | 0.30 | 6,053 | 1,816 | 6,108 | 09/05/23 |